Pasar al contenido principal

Biología Molecular del Cáncer

IJCI-2016-28201

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de Promoción del Talento y su Empleabilidad en I+D+i
Subprograma Subprograma Estatal de Incorporación
Convocatoria Juan de la Cierva Incorporación
Año convocatoria 2016
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACIO INSTITUT D INVESTIGACIO BIOMEDICA DE BELLVITGE (IDIBELL)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

SMARCA4 deficient tumours are vulnerable to KDM6A/UTX and KDM6B/JMJD3 blockade

  • Romero, Octavio A.|||0000-0003-0229-6530
  • Vilarrubi, Andrea|||0000-0002-2930-3246
  • Alburquerque-Béjar, Juan Jos|||0000-0002-9022-124X
  • Gómez Moruno, Antonio|||0000-0001-5308-981X
  • Andrades, Álvaro
  • Trastulli, Deborah|||0000-0003-2407-3290
  • Pros, Eva|||0000-0002-2366-7866
  • Setien, Fernando|||0000-0002-4061-4635
  • Verdura, Sara|||0000-0001-8980-0423
  • Farré, Lourdes|||0000-0002-3168-1940
  • Martín-Tejera, Juan F.
  • Llabata, Paula|||0000-0001-7733-6475
  • Oaknin, Ana|||0000-0002-3592-7194
  • Saigí, Maria|||0000-0001-5815-5388
  • Piulats, Josep M.|||0000-0002-3606-1724
  • Matías-Guiu, Xavier|||0000-0002-7201-6605
  • Medina, Pedro P.
  • Vidal, August|||0000-0001-5727-2099
  • Villanueva, Alejandro|||0000-0001-5164-0006
  • Sánchez Céspedes, Montse|||0000-0002-6045-5627
Despite the genetic inactivation of SMARCA4, a core component of the SWI/SNF-complex commonly found in cancer, there are no therapies that effectively target SMARCA4-deficient tumours. Here, we show that, unlike the cells with activated MYC oncogene, cells with SMARCA4 inactivation are refractory to the histone deacetylase inhibitor, SAHA, leading to the aberrant accumulation of H3K27me3. SMARCA4-mutant cells also show an impaired transactivation and significantly reduced levels of the histone demethylases KDM6A/UTX and KDM6B/JMJD3, and a strong dependency on these histone demethylases, so that its inhibition compromises cell viability. Administering the KDM6 inhibitor GSK-J4 to mice orthotopically implanted with SMARCA4-mutant lung cancer cells or primary small cell carcinoma of the ovary, hypercalcaemic type (SCCOHT), had strong anti-tumour effects. In this work we highlight the vulnerability of KDM6 inhibitors as a characteristic that could be exploited for treating SMARCA4-mutant cancer patients.